Últimos Artículos de Lancet Diabetes & Endocrinology
- [Correspondence] Causal inference in perinatal epidemiology: big data's false promises
- [Editorial] Sleep your way to better metabolic health
- [Comment] USP8 genotype and tumour size as predictors for recurrence in Cushing's disease
- [Articles] Risk of recurrence after successful surgery for Cushing's disease and association with USP8 genotype and tumour size: an international, retrospective, longitudinal cohort study
- [Corrections] Correction to Lancet Diabetes Endocrinol 2026; 14: 317–26
- [Correspondence] Autologous and allogeneic stem cell-derived islet therapy in three recipients with type 1 diabetes and complete loss of endogenous pancreatic β-cell function pretransplant
- [Personal View] From survival to freedom: redefining success in type 1 diabetes
- [Articles] Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study
- [Comment] Additional benefits of combining GLP-1 receptor agonist use with lifestyle modification
- [Comment] Reuniting diabetes through the islet coordinate framework
- [Articles] Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA1c (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trial
- [Comment] Automated insulin delivery systems and improved glycaemic outcomes in type 1 diabetes: what comes next?
- [Review] Diabetes and mental health
- [Articles] Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study
- [Comment] Specific cortisol blockade in Cushing's syndrome
- [Comment] Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2025
- [Comment] Prioritising nutrition alongside paediatric obesity management medications
- [In Focus] Quest for the holy grail: an effective drug for obesity
- [Editorial] A new dawn for osteoporosis drug development
- [Comment] 3 months of romosozumab: a pragmatic clinical solution